Amgen Inc. Senior Vice President for Global Value, Access and Policy Josh Ofman has participated in the negotiation of value-based contracts for the company's portfolio of biologics and sees the agreements as one area where both sides are optimistic about putting an appropriate value on innovative medicines.
However, Ofman said in an interview with Scrip during the BIO International Convention in June that there are many challenges...